ES2309299T3 - Tratamiento de la artritis reumatoide usando imatinib. - Google Patents

Tratamiento de la artritis reumatoide usando imatinib. Download PDF

Info

Publication number
ES2309299T3
ES2309299T3 ES03704474T ES03704474T ES2309299T3 ES 2309299 T3 ES2309299 T3 ES 2309299T3 ES 03704474 T ES03704474 T ES 03704474T ES 03704474 T ES03704474 T ES 03704474T ES 2309299 T3 ES2309299 T3 ES 2309299T3
Authority
ES
Spain
Prior art keywords
study
compound
sal
rheumatoid arthritis
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03704474T
Other languages
English (en)
Spanish (es)
Inventor
Heikki Joensuu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinki University Hospital
Original Assignee
Helsinki University Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinki University Hospital filed Critical Helsinki University Hospital
Application granted granted Critical
Publication of ES2309299T3 publication Critical patent/ES2309299T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES03704474T 2002-01-28 2003-01-27 Tratamiento de la artritis reumatoide usando imatinib. Expired - Lifetime ES2309299T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201882.8A GB0201882D0 (en) 2002-01-28 2002-01-28 Organic compounds
GB0201882 2002-01-28

Publications (1)

Publication Number Publication Date
ES2309299T3 true ES2309299T3 (es) 2008-12-16

Family

ID=9929858

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03704474T Expired - Lifetime ES2309299T3 (es) 2002-01-28 2003-01-27 Tratamiento de la artritis reumatoide usando imatinib.

Country Status (22)

Country Link
US (2) US20060264443A1 (enExample)
EP (1) EP1471916B1 (enExample)
JP (1) JP4398731B2 (enExample)
KR (1) KR101030416B1 (enExample)
CN (1) CN1646130A (enExample)
AT (1) ATE399555T1 (enExample)
BR (1) BR0307286A (enExample)
CA (1) CA2473158C (enExample)
DE (1) DE60321888D1 (enExample)
DK (1) DK1471916T3 (enExample)
ES (1) ES2309299T3 (enExample)
GB (1) GB0201882D0 (enExample)
IL (1) IL162983A (enExample)
MX (1) MXPA04007309A (enExample)
NO (1) NO328255B1 (enExample)
NZ (1) NZ534137A (enExample)
PL (1) PL212137B1 (enExample)
PT (1) PT1471916E (enExample)
RU (1) RU2322238C2 (enExample)
SI (1) SI1471916T1 (enExample)
WO (1) WO2003063844A2 (enExample)
ZA (1) ZA200405323B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479257A1 (en) * 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
US20050130986A1 (en) * 2003-11-21 2005-06-16 Eklund Kari K. Treatment of spondylarthropathies
US20080248022A1 (en) * 2004-09-08 2008-10-09 Immunaid Pty Ltd Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases
JP2010500283A (ja) * 2006-05-31 2010-01-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
CN102512421B (zh) * 2011-10-28 2013-11-06 中国科学院广州生物医药与健康研究院 哌嗪酰胺类化合物在制药中的应用
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
RU2580656C1 (ru) * 2014-11-20 2016-04-10 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма гидроксихлорохина немедленного высвобождения и способ ее получения
US20210380685A1 (en) * 2018-10-18 2021-12-09 Sinomab Bioscience Limited Methods of Treating Rheumatoid Arthritis
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316884A (en) * 1979-01-25 1982-02-23 Adria Laboratories, Inc. Sustained release pharmaceutical formulation
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW550258B (en) * 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
EP1414500A4 (en) * 2001-04-16 2005-01-12 Uab Research Foundation Akt and regulation of ra synovial fibroblast apoptosis
AU2002342335B2 (en) * 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
ATE330608T1 (de) * 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen

Also Published As

Publication number Publication date
ATE399555T1 (de) 2008-07-15
HK1072192A1 (en) 2005-08-19
EP1471916B1 (en) 2008-07-02
US20090131382A1 (en) 2009-05-21
NO20043585L (no) 2004-10-21
NO328255B1 (no) 2010-01-18
PL212137B1 (pl) 2012-08-31
PT1471916E (pt) 2008-10-03
WO2003063844A3 (en) 2004-04-01
KR20040086301A (ko) 2004-10-08
WO2003063844A2 (en) 2003-08-07
JP4398731B2 (ja) 2010-01-13
PL370264A1 (en) 2005-05-16
NZ534137A (en) 2007-03-30
IL162983A (en) 2010-06-16
JP2005526022A (ja) 2005-09-02
ZA200405323B (en) 2005-08-31
RU2322238C2 (ru) 2008-04-20
MXPA04007309A (es) 2005-09-12
EP1471916A2 (en) 2004-11-03
US20060264443A1 (en) 2006-11-23
DE60321888D1 (enExample) 2008-08-14
CN1646130A (zh) 2005-07-27
DK1471916T3 (da) 2008-10-20
CA2473158A1 (en) 2003-08-07
RU2004126447A (ru) 2005-07-10
SI1471916T1 (sl) 2008-12-31
GB0201882D0 (en) 2002-03-13
BR0307286A (pt) 2004-12-28
CA2473158C (en) 2013-06-11
KR101030416B1 (ko) 2011-04-20

Similar Documents

Publication Publication Date Title
US20190099429A1 (en) Cenicriviroc for the treatment of fibrosis
US20090131382A1 (en) Treatment of rheumatoid arthritis using imatinib
US12427142B2 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
CN116261463A (zh) 治疗痛风的方法
CN116782895A (zh) 包含阿贝西利和6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸的组合
AU2016319292A1 (en) Use of interleukin 2 for treating spondyloarthritis
ES2880950T3 (es) Terapia de anticuerpos contra el VIH como sustituto del tratamiento
MXPA02008756A (es) Terapia adyuvante inmune de virus de inmunodeficiencia humana.
JP2005526022A5 (ja) 関節リウマチの処置
Dalakas Therapeutic advances and future prospects in immune-mediated inflammatory myopathies
US20230000822A1 (en) A combination of a btk inhibitor and abatacept for the treatment of rheumatoid arthritis
AU2007201056B2 (en) Treatment of rheumatoid arthritis using imatinib
JP2000256211A (ja) Ｈｉｖ治療薬
HK1072192B (en) Treatment of rheumatoid arthritis using imatinib
Adams New relief for gout
US20050130986A1 (en) Treatment of spondylarthropathies
AU2003206783A1 (en) Treatment of rheumatoid arthritis using imatinie
US20210121464A1 (en) Methotrexate for use as a medicament
O'Horo Canakinumab
TW202539688A (zh) 使用索樂匹尼布處置溫型自體免疫性溶血性貧血的方法
Alivernini et al. Drugs in Focus in Arthritis: Leflunomide
UA12320U (en) Method for treating patients with rheumatoid arthritis involving heart